|
Characteristic
|
Crude HR (95% CI)
|
P-value* (bivariatea)
|
Adjusted HR (95% CI)
|
P-value* (multivariablea)
|
|---|
|
Primary tumor location
|
|
Right vs. Left
|
2.29 (1.46–3.62)
|
<0.001
|
1.84 (1.10–3.09)
|
0.021
|
|
Age
|
|
>60 years vs. ≤ 60
|
1.06 (0.76–1.47)
|
0.750
|
1.07 (0.75–1.51)
|
0.720
|
|
Gender
|
|
Female vs. Male
|
0.92(0.65–1.30)
|
0.623
|
0.97 (0.66–1.40)
|
0.852
|
|
Stage at presentation
|
|
Stage IV vs. Stage I-III
|
1.12 (0.77–1.63)
|
0.554
| | |
|
Histologic grade
|
|
P/D or SRC vs. W/D or M/D
|
4.35 (2.21–8.57)
|
<0.001
|
3.08 (1.49–6.34)
|
0.002
|
|
Presence of liver metastasis
|
|
Yes vs. No
|
1.29 (0.91–1.82)
|
0.156
| | |
|
Presence of lung metastasis
|
|
Yes vs. No
|
0.84 (0.61–1.15)
|
0.279
| | |
|
Presence of peritoneal metastasis
|
|
Yes vs. No
|
2.91 (1.79–4.75)
|
<0.001
|
2.05 (1.17–3.60)
|
0.013
|
|
Number of metastasized organs
|
|
≥ 2 vs. 1
|
1.10 (0.80–1.52)
|
0.540
| | |
|
BRAF
|
|
Mutant vs. Wild-type
|
3.24 (1.94–5.43)
|
<0.001
|
2.84 (1.60–5.03)
|
<0.001
|
|
PIK3CA
|
|
Mutant vs. Wild-type
|
1.97 (0.80–4.84)
|
0.138
| | |
- Abbreviations: HR hazard ratio, CI confidence interval, P/D poorly differentiated, SRCC signet ring cell carcinoma, W/D well-differentiated, M/D moderately differentiated
-
*
P-value by Cox’s proportional hazards regression
-
aClinically meaningful variables and those with p < 0.05 by bivariate analysis were entered into the multivariable analysis model
